Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:pioglitazone
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
1999
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A10BG03
|
| gptkbp:contraindication |
heart failure
bladder cancer |
| gptkbp:drugClass |
thiazolidinedione
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:form |
gptkb:tablet
|
| gptkbp:halfLife |
16-24 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Actos
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceuticals
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:sideEffect |
heart failure
edema weight gain risk of bladder cancer |
| gptkbp:synonym |
pioglitazone hydrochloride
|
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:bfsParent |
gptkb:Takeda
gptkb:Takeda_(Japan) |
| gptkbp:bfsLayer |
6
|